What is the recommended evaluation and management for a patient with Lynch syndrome?

Lynch Syndrome: Evaluation and Management

All patients with colorectal cancer should undergo universal tumor screening with either immunohistochemistry (IHC) or microsatellite instability (MSI) testing to identify Lynch syndrome, and confirmed carriers require colonoscopy surveillance every 1-2 years starting at age 20-25 (or 5 years before youngest family diagnosis), with aspirin chemoprevention offered for cancer risk reduction. 1

Identification and Diagnosis

Who Should Be Tested

Universal tumor screening is strongly recommended for all patients diagnosed with colorectal cancer, regardless of age 1. This represents a paradigm shift from selective testing, as Lynch syndrome can present even in elderly patients and has critical implications for family members.

Diagnostic Algorithm

Step 1: Initial Tumor Testing

• Perform IHC for MLH1, MSH2, MSH6, and PMS2 proteins OR MSI testing on tumor tissue 1
• Both methods have comparable sensitivity and specificity; choice depends on institutional expertise
• Critical caveat: Pathologists must have appropriate training in IHC interpretation, and systematic follow-up protocols must be established 1

Step 2: Reflex Testing for MLH1 Loss

• If IHC shows absent MLH1, perform BRAF V600E mutation testing or MLH1 promoter hypermethylation analysis before proceeding to germline testing 1
• Approximately 75% of MLH1-absent tumors are sporadic cancers, not Lynch syndrome 1
• If BRAF mutation or hypermethylation is positive, Lynch syndrome is extremely unlikely
• Important limitation: Up to 10% of Lynch syndrome cases may have BRAF mutations or hypermethylation, so some cases could be missed with this approach 1

Step 3: Germline Genetic Testing

• Proceed to germline MMR gene testing if:
  • IHC shows loss of MSH2, MSH6, or PMS2
  • MLH1 loss without BRAF mutation or hypermethylation

Risk Prediction Models for Unaffected Individuals

For patients with suggestive family history but no personal cancer diagnosis, use validated prediction models 2:

• PREMM5 model: Threshold ≥5% for genetic evaluation (≥2.5% is reasonable with clinical judgment)
• MMRPredict or MMRpro: Alternative validated models
• Clinical criteria warranting evaluation 2:
  • ≥3 relatives with Lynch-related cancers (colorectal, endometrial, gastric, ovarian, urinary tract, small bowel, brain, sebaceous)
  • ≥2 first/second-degree relatives with Lynch cancers, one diagnosed <50 years
  • 1 first-degree relative with colorectal or endometrial cancer AND another synchronous/metachronous Lynch cancer

Surveillance and Cancer Prevention

Colonoscopy Surveillance

Surveillance colonoscopy dramatically reduces both colorectal cancer incidence (77% reduction) and mortality (94% reduction) compared to no surveillance, increasing life expectancy by 7 years 1.

Surveillance protocol 1:

• Start age: 20-25 years OR 5 years before youngest affected family member (whichever comes first)
• Interval: Every 1-2 years
• After age 40: Consider annual surveillance
• Gene-specific considerations 3:
  • MLH1/MSH2 carriers: Start at age 25
  • MSH6/PMS2 carriers: Can start at age 35 (lower early cancer risk)

Technical requirements 3:

• Use high-definition endoscopy systems
• Consider chromoendoscopy for enhanced detection (though not universally required)
• Surveillance should occur in dedicated units monitoring compliance and performance

Aspirin Chemoprevention

Aspirin 600 mg daily reduces colorectal cancer incidence by 44% beyond colonoscopy surveillance alone in a randomized controlled trial 1. The AGA conditionally recommends offering aspirin for cancer prevention 1.

Practical considerations:

• Evidence supports 600 mg daily dosing
• Benefits observed after 4+ years of use
• Must weigh bleeding risks against cancer prevention benefits
• No mortality benefit was demonstrated in the primary trial

Gynecologic Surveillance and Prevention

For women with Lynch syndrome 4:

• Endometrial cancer risk: 40-60% lifetime risk
• Ovarian cancer risk: 8-10% lifetime risk
• Surveillance: Annual transvaginal ultrasound and endometrial biopsy starting age 30-35 (though evidence for effectiveness is limited)
• Risk-reducing surgery: Hysterectomy with bilateral salpingo-oophorectomy after childbearing is frequently recommended
• Hormonal prevention: Oral contraceptives may reduce endometrial cancer risk by up to 50%

Other Cancer Surveillance

Current guidelines show significant variability 5:

• Gastric cancer: Inconsistent recommendations; consider in high-risk populations or families
• Urinary tract: Most guidelines recommend surveillance only with positive family history
• Pancreas/small bowel: Routine surveillance not recommended by most societies

Surgical Management Considerations

When colorectal cancer develops in Lynch syndrome patients, there is significant disagreement between guidelines regarding extent of resection (limited vs. extended colectomy) 5. This decision should incorporate:

• Patient age and life expectancy
• Gene-specific metachronous cancer risk
• Patient preference regarding surveillance burden
• Functional outcomes

Common Pitfalls

1. Failing to test elderly patients: Lynch syndrome occurs at all ages, and family implications remain critical
2. Skipping reflex BRAF/hypermethylation testing: Leads to unnecessary germline testing and patient anxiety
3. Inadequate pathology expertise: IHC interpretation requires specialized training
4. Lack of systematic follow-up: Positive screening results must trigger definitive genetic counseling and testing
5. Gene-agnostic surveillance: MSH6 and PMS2 carriers have lower early cancer risk, allowing later surveillance initiation 3

Implementation Challenges

Despite strong evidence, universal tumor screening implementation remains slow 2. Barriers include lack of systematic protocols, inadequate genetic counseling resources, and variable institutional expertise. Establishing dedicated Lynch syndrome programs with monitoring systems improves outcomes 3.